148 related articles for article (PubMed ID: 22490898)
21. Antiproliferative and overadditive effects of everolimus and mycophenolate mofetil in pancreas and lung cancer cells in vitro.
Stracke S; Ramudo L; Keller F; Henne-Bruns D; Mayer JM
Transplant Proc; 2006 Apr; 38(3):766-70. PubMed ID: 16647466
[TBL] [Abstract][Full Text] [Related]
22. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis.
Duncan FJ; Wulff BC; Tober KL; Ferketich AK; Martin J; Thomas-Ahner JM; Allen SD; Kusewitt DF; Oberyszyn TM; Vanbuskirk AM
Am J Transplant; 2007 Dec; 7(12):2693-703. PubMed ID: 17941958
[TBL] [Abstract][Full Text] [Related]
23. Corticosteroids do not reverse the inhibitory effect of cyclosporine on regulatory T-cell activity in contrast to mycophenolate mofetil.
Miroux C; Morales O; Ouaguia L; Aoudjehane L; Boleslawski E; Pancré V; de Launoit Y; Calmus Y; Conti F; Delhem N
Transplant Proc; 2012 Nov; 44(9):2834-9. PubMed ID: 23146536
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of mycophenolate mofetil and cyclosporine A on peripheral blood and cord blood natural killer cells activated with interleukin-2.
Derniame S; Perazzo J; Lee F; Domogala A; Escobedo-Cousin M; Alnabhan R; Luevano M; Pedroza-Pacheco I; Cooper N; Madrigal A; Saudemont A
Cytotherapy; 2014 Oct; 16(10):1409-18. PubMed ID: 24969967
[TBL] [Abstract][Full Text] [Related]
25. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
[TBL] [Abstract][Full Text] [Related]
26. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis--implications for post-transplantation bone disease.
Westenfeld R; Schlieper G; Wöltje M; Gawlik A; Brandenburg V; Rutkowski P; Floege J; Jahnen-Dechent W; Ketteler M
Nephrol Dial Transplant; 2011 Dec; 26(12):4115-23. PubMed ID: 21622987
[TBL] [Abstract][Full Text] [Related]
27. Effect of cyclosporine and sirolimus on fatty acid desaturase activities in cultured HEPG2 cells.
Lausada N; de Gómez Dumm IN; Raimondi JC; de Alaniz MJ
Transplant Proc; 2009 Jun; 41(5):1865-70. PubMed ID: 19545746
[TBL] [Abstract][Full Text] [Related]
28. Synergistic effects of mycophenolate mofetil and losartan in a model of chronic cyclosporine nephropathy.
Yang CW; Ahn HJ; Kim WY; Li C; Jung JY; Yoon SA; Kim YS; Cha JH; Kim J; Bang BK
Transplantation; 2003 Feb; 75(3):309-15. PubMed ID: 12589150
[TBL] [Abstract][Full Text] [Related]
29. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
Weir MR; Mulgaonkar S; Chan L; Shidban H; Waid TH; Preston D; Kalil RN; Pearson TC
Kidney Int; 2011 Apr; 79(8):897-907. PubMed ID: 21191361
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.
Ruggenenti P; Perico N; Gotti E; Cravedi P; D'Agati V; Gagliardini E; Abbate M; Gaspari F; Cattaneo D; Noris M; Casiraghi F; Todeschini M; Cugini D; Conti S; Remuzzi G
Transplantation; 2007 Oct; 84(8):956-64. PubMed ID: 17989600
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.
Birnbaum F; Böhringer D; Sokolovska Y; Sundmacher R; Reinhard T
Transplantation; 2005 Apr; 79(8):964-8. PubMed ID: 15849551
[TBL] [Abstract][Full Text] [Related]
32. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation.
Guba M; Pratschke J; Hugo C; Krämer BK; Pascher A; Pressmar K; Hakenberg O; Fischereder M; Brockmann J; Andrassy J; Banas B; Jauch KW;
Transpl Int; 2012 Apr; 25(4):416-23. PubMed ID: 22320241
[TBL] [Abstract][Full Text] [Related]
33. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts.
Shimizu H; Takahashi M; Takeda S; Inoue S; Fujishiro J; Hakamata Y; Kaneko T; Murakami T; Takeyoshi I; Morishita Y; Kobayashi E
Transpl Immunol; 2004 Nov; 13(3):219-27. PubMed ID: 15381205
[TBL] [Abstract][Full Text] [Related]
34. Effects of cyclosporine and sirolimus on insulin-stimulated glucose transport and glucose tolerance in a rat model.
Lopes P; Fuhrmann A; Sereno J; Pereira MJ; Nunes P; Pedro J; Melão A; Reis F; Carvalho E
Transplant Proc; 2013 Apr; 45(3):1142-8. PubMed ID: 23622647
[TBL] [Abstract][Full Text] [Related]
35. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
36. Sirolimus and mycophenolate mofetil after liver transplantation.
Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
[TBL] [Abstract][Full Text] [Related]
37. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor.
Durrbach A; Rostaing L; Tricot L; Ouali N; Wolf P; Pouteil-Noble C; Kessler M; Viron B; Thervet E
Transplantation; 2008 Feb; 85(3):486-90. PubMed ID: 18301342
[TBL] [Abstract][Full Text] [Related]
38. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Inoue K; Karashima T; Fukata S; Nomura A; Kawada C; Kurabayashi A; Furihata M; Ohtsuki Y; Shuin T
Clin Cancer Res; 2005 Sep; 11(18):6669-77. PubMed ID: 16166446
[TBL] [Abstract][Full Text] [Related]
39. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
40. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.
Flechner SM; Zhou L; Derweesh I; Mastroianni B; Savas K; Goldfarb D; Modlin CS; Krishnamurthi V; Novick A
Transplantation; 2003 Dec; 76(12):1729-34. PubMed ID: 14688524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
